Investigator-Sponsored Protocol - Continued Use of Ibalizumab

Ibalizumab is to be administered to HIV-infected patients that have responded (defined as a
minimum 0.7 log10 decline in HIV-1 viral load from TMB-202 Baseline) on the TMB-202 protocol.
In addition to the investigator-selected Optimized Background Regimen, patient(s) will
continue to receive the TMB-202 randomized dose of ibalizumab in open-labeled fashion (800mg
IV every two weeks or 2000mg IV every four weeks) as per their original drug assignment for
the TMB-202 protocol.

Inclusion Criteria:

- Capable of understanding and have voluntarily signed the ICF

- Have documented HIV-1 infection

- Have successfully completed Protocol TMB202 (Amendment 2)(Week 16)

- Have had at least a 0.7 log10 decline in HIV-1 RNA from baseline at Week 16 and beyond
while in TMB202 and are no longer eligible to participate in TMB-202 due to TMB-202
protocol-defined virologic failure

- Have not withdrawn or been discontinued from TMB202 9Amendment 2) for any reason

- Are able and willing to comply with all protocol requirements and procedures

- Are 18 years of age or older

- If sexually active, are willing to use an effective method of contraception during the
study and for 30days after the last administration of the study drug.

Exclusion Criteria:

- Any active AIDS-defining illness per Category C except for cutaneous Kaposi's sarcoma
and wasting due to HIV

- Any significant disease (other than HIV-1 infection) or clinically significant
findings, including psychiatric and behavioral problems, medical history and/or
physical examination that, in the investigator's opinion, would preclude the patient
from participating in this study

- Any current alcohol or illicit drug use that, in the investigator's opinion, will
interfere with the patient's ability to comply with the study schedule and protocol
evaluations

- Any previous clinically significant allergy or hypersensitivity to any excipient in
the ibalizumab formulation